MedTrace Logo

Evaluating an Intervention to Increase Use of Call Centre Support for Self-managed Medical Abortion

NCT03248050 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1359

Last updated 2017-08-14

No results posted yet for this study

Summary

Self-management of medical abortion (MA) pills purchased from pharmacies is considered to be one of the reasons behind falling morbidity and mortality from unsafe abortion in recent years. While pharmacy workers commonly sell MA medications over the counter, they have inadequate knowledge about how women should take the medications and their potential complications, and do not offer adequate information and counselling to women buying the drugs. This study aims to evaluate if a pharmacy-based intervention to promote use of a support hotline (Marie Stopes Zambia (MSZ) call centre) among MA purchasers can increase use of the call centre, and to assess whether correct MA use and acceptability of self- administered MA is higher among MA users who contact the call centre than those who self-administer MA without call centre support.

Conditions

  • Abortion, Drug-Induced
  • Pharmacies

Interventions

BEHAVIORAL

Pharmacy encouraged to promote call centre use to clients

The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.

Sponsors & Collaborators

  • Marie Stopes International

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-15
Primary Completion
2018-04-15
Completion
2018-06-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03248050 on ClinicalTrials.gov